A U.K. study of 877 transcatheter aortic valve implant procedures done from January 2007 to December 2009 found that patients who received Medtronic's CoreValve had lower death rates, while patients who received Edwards Lifesciences' Sapien device had reduced rates of repeat procedures and pacemaker use. Edwards anticipates FDA clearance for its device soon, while Medtronic expects its device to be available in the U.S. market by 2014.

Related Summaries